Scarica l'app Stockscreener
17.14
1.44%
-0.25
Dopo l'orario di chiusura:
17.61
0.47
+2.74%
Precedente Chiudi:
$17.39
Aprire:
$17.38
Volume 24 ore:
1.09M
Relative Volume:
0.35
Capitalizzazione di mercato:
$1.07B
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-4.924
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+4.83%
1M Prestazione:
+20.11%
6M Prestazione:
-70.41%
1 anno Prestazione:
+95.66%
Intervallo 1D:
$16.65
$17.46
Intervallo di 1 settimana:
$16.29
$17.69
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
17.14 | 1.09B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE - GlobeNewswire Inc.
FDA Criticizes uniQure's Gene Therapy, Lawsuit Filed - National Today
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - TMX Newsfile
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - PR Newswire
uniQure N.V. Faces Class Action Lawsuit Deadline - National Today
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors ... - Caledonian Record
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - GlobeNewswire Inc.
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
uniQure Faces FDA Rebuke as Shareholder Class Action Filed - Intellectia AI
uniQure Approaches April 13 Court Deadline Amid Stricter FDA Position on Gene Therapy Study - Bitget
QURE INVESTOR NOTICE: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears - ChartMill
(QURE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure - GlobeNewswire
QURE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
Aberdeen Group plc Acquires 738,897 Shares of uniQure N.V. $QURE - MarketBeat
uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
uniQure N.V. Class Action Reminder - National Today
uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm fo - PharmiWeb.com
uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights - The Daily Tribune News
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - PR Newswire
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears - PR Newswire
UniQure surges following departure of key FDA official - MSN
UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure ... - Caledonian Record
UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - GlobeNewswire Inc.
UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
2026-04-02 | QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 | NDAQ:QURE | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Eastern Progress
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - PR Newswire
Rare disease advocacy group urges Trump administration to restore FDA clarity - MarketScreener
Barclays Reaffirms Equal Weight Rating for uniQure (QURE) - Insider Monkey
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay - Intellectia AI
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
QURE jumps 20% – analysts upgrade stock on Huntington’s disease therapy update, retail eyes $150 - MSN
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart.com
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - ChartMill
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Deadline Approaching for uniQure N.V. Class Action Lawsuit - National Today
Contact Levi & Korsinsky by April 13, 2026 Deadline to Join Class Action Against uniQure N.V. (QURE) - GlobeNewswire
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - ChartMill
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz - GuruFocus
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline - PR Newswire
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
2.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):